Esperion Therapeutics Q2 Revenue Rises

TL;DR

Esperion Q2 revenue up to $102.8M, showing growth.

AI Summary

Esperion Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported product revenue of $102.8 million for the second quarter of 2024, an increase from $97.4 million in the same period of 2023. For the six months ended June 30, 2024, product revenue was $203.4 million, up from $190.6 million in the prior year.

Why It Matters

The increase in product revenue suggests positive sales momentum for Esperion's pharmaceutical products, which could impact investor confidence and future financial performance.

Risk Assessment

Risk Level: medium — While revenue is increasing, the company's financial health and ability to achieve profitability remain key concerns for investors.

Key Numbers

• $102.8M — Q2 2024 Product Revenue (Represents an increase compared to Q2 2023.)
• $203.4M — YTD June 30, 2024 Product Revenue (Shows year-to-date growth compared to the same period in 2023.)
• $97.4M — Q2 2023 Product Revenue (Baseline for Q2 2024 revenue comparison.)
• $190.6M — YTD June 30, 2023 Product Revenue (Baseline for YTD 2024 revenue comparison.)

Key Players & Entities

• Esperion Therapeutics, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of reporting period
• $102.8 million (dollar_amount) — Product revenue for Q2 2024
• $97.4 million (dollar_amount) — Product revenue for Q2 2023
• $203.4 million (dollar_amount) — Product revenue for the six months ended June 30, 2024
• $190.6 million (dollar_amount) — Product revenue for the six months ended June 30, 2023

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC

Filing Documents

• espr-20240630.htm (10-Q) — 1071KB
• exhibit101royaltysaleagree.htm (EX-10.1) — 353KB
• espr-ex311x06302024.htm (EX-31.1) — 11KB
• espr-ex312x06302024.htm (EX-31.2) — 11KB
• espr-ex321x06302024.htm (EX-32.1) — 8KB
• 0001628280-24-036762.txt ( ) — 6838KB
• espr-20240630.xsd (EX-101.SCH) — 63KB
• espr-20240630_cal.xml (EX-101.CAL) — 51KB
• espr-20240630_def.xml (EX-101.DEF) — 297KB
• espr-20240630_lab.xml (EX-101.LAB) — 611KB
• espr-20240630_pre.xml (EX-101.PRE) — 449KB
• espr-20240630_htm.xml (XML) — 742KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Balance Sheets at June 3 0 , 2024 and December 31, 2023 3 Condensed Statements of Operations and Comprehensive Loss for the three and six month periods ended June 3 0 , 2024 and 2023 4 Condensed Statements of Stockholders' Deficit for the three and six month periods ended June 3 0 , 2024 and 2023 5 Condensed Statements of Cash Flows for the six month periods ended June 3 0 , 2024 and 2023 7 Notes to Condensed Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 41

Controls and Procedures

Item 4. Controls and Procedures 41

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 42

Exhibits

Item 6. Exhibits 47

Signatures

Signatures 49 From time to time, we may use our website, our X (formerly Twitter) account (@EsperionInc) or our LinkedIn profile at www.linkedin.com/company/esperion-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors & Media section of our website, available at www.esperion.com. Investors are encouraged to review the Investors & Media section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report on Form 10-Q. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. This Quarterly Report on Form 10-Q may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties' trademarks, service marks, trade names or products in this Quarterly Report on Form 10-Q is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the and symbols, but the omission of such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 Table of Contents Esperion Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share data) June 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 189,304 $ 82,248 Accounts receivable 60,360 48,494 Prepaid clinical development costs 349 193 Inventories, net 84,469 65,623 Other prepaid and current assets 10,626 4,507 Total current assets 345,108 201,065

View Full Filing

View this 10-Q filing on SEC EDGAR